Ligand Pharmaceuticals (LGND) Gross Margin (2011 - 2026)

Ligand Pharmaceuticals has disclosed Gross Margin across 16 years of filings, most recently posting 93.67% for Q1 2026.

• Gross Margin for Q1 2026 came in at 93.67%, up 437.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 95.27% (up 246.0% YoY), and the FY2025 annual result was 94.57%, up 120.0% from the prior year.
• Gross Margin came in at 93.67% for Q1 2026 at Ligand Pharmaceuticals, down from 94.99% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 96.71% in Q3 2025 to a low of 57.1% in Q4 2022.
• The 5-year median for Gross Margin is 93.0% (2024), against an average of 88.55%.
• Across the five-year window, Gross Margin slumped 2165 bps in 2022 and soared 3706 bps in 2023, its largest moves.
• Ligand Pharmaceuticals' Gross Margin stood at 57.1% in 2022, then soared by 65 bps to 94.16% in 2023, then slipped by 1 bps to 93.37% in 2024, then increased by 2 bps to 94.99% in 2025, then retreated by 1 bps to 93.67% in 2026.
• The last three Gross Margin figures came in at 93.67% (Q1 2026), 94.99% (Q4 2025), and 96.71% (Q3 2025), per Business Quant data.